13, 26, 27 These histological and clinical features are distinct from classical descriptions of acute allograft rejection.28 Hepatotoxicity due to certain drugs can also target the centrilobular
region; halothane hepatitis, the best defined, results from metabolic idiosyncrasy and autoantibody formation toward antigens located within pericentral hepatocytes.30 Therefore, it seems plausible that specific antigens, whether environmental, drug-derived, or expressed on non-self hepatocytes, may trigger an immune-mediated injury to the centrilobular region by targeting http://www.selleckchem.com/products/apo866-fk866.html antigens preferentially expressed by zone three hepatocytes. The fact that no true gold standard exists for the diagnosis of AIH represents a limitation of our observations. Accordingly, we reasoned that patients with bona fide AI-ALF would more often develop chronic hepatitis in their native livers (in spontaneous
survivors) or allografts (in transplant recipients) than those with indeterminate ALF. After CT99021 datasheet 1-4 years follow-up, we found a high (44%) incidence of hepatitis in the study population, and those with histologically proven hepatitis were more frequently those with positive ANA ± ASMA who were given a final histological diagnosis of probable AI-ALF. These data seem further supported by the fact that none of these markers of autoimmunity before transplant were associated with allograft rejection (data not shown). The clinical relevance of non–organ specific autoantibodies in ALF remains uncertain. A recent screen of ANA, ASMA, AMA, and LKM autoantibodies in patients with ALF revealed a prevalence of 25% in patients with non-acetaminophen drug reactions and hepatotrophic viral infections, but in none of patients with
acetaminophen-induced see more ALF,31 suggesting that their presence may nonspecifically accompany overwhelming immune activation. Our observations suggest that the presence of autoantibodies correlate with histological diagnosis of AI-ALF. Specifically, patients with AI-ALF more frequently had ANA and/or ASMA, and anti-LKM, anti-SLA, and anti-tTG were exclusively detected in patients with histological AI-ALF (data not shown). Moreover, the addition of ANA ± ASMA to a histological diagnosis of AI-ALF appeared to improve the detection of histology alone to identify an autoimmune phenotype. In conclusion, we propose that four histological features of autoimmune liver disease can be interpreted as probable AI-ALF. Patients with probable AI-ALF on histology have a distinctly autoimmune clinical phenotype, and the presence of ANA and/or ASMA may improve the distinction of AI-ALF from other cases of indeterminate ALF. Similar to aggressive, refractory cases of acute cellular allograft rejection, centrilobular necroinflammatory features appear to be a hallmark of AI-ALF.